SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

Overhaul of EU health systems good opportunity for outcomes data providers, says Quintiles

By Natalie Morrison , 07-Jun-2012
Last updated on 07-Jun-2012 at 14:16 GMT

Value based drugs pricing: Market gap for outsource firms, Quintiles
Value based drugs pricing: Market gap for outsource firms, Quintiles
Loading...

Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.

The firm recently launched a briefing paper, which looks at market access strategies and how they can help biopharmaceutical firms dodge the risks creating by the fragmented industry across the continent.

Quintiles published the report in the wake of discussions in all over Europe about value-based pricing for drugs - where the medicine is priced based on its need in the local area.

Speaking to Outsourcing-Pharma.com, the paper’s author Gareth Williams - UK market access director – said the key thing to consider in the face of the changes is collecting outcomes data to “understand the fabric of local health authorities”, and what is important to them.

And for many firms, the easiest way to work closely with the local authorities in the “fragmented” European healthcare systems is outsourcing.

However, he told us that not all firms will outsource, and that service providers will probably see the biggest influx from biopharma’s with less consistent pipelines. In other words, not from Big Pharma which is likely to have staff on the ground.

“I think the biggest predictor of whether a company will outsource is depending on their pipeline coming through,” he said. “It’s quite an expensive resource to have if you don’t have a consistent pipeline of those products coming through once every 12 months.”

The cost of success

Of added costs to working with providers who specialise in the individual markets and systems, Williams said biopharmas need not worry.

He said: “If the reason you’re collecting outcomes data is to help inform subsequent years’ budget then you could displace how you currently promote the medicine and use the budget set aside for that for outcomes data instead.

"As Europe moves to wards value based pricing I think that is more and more important."

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Related products

A bitter pill to swallow: young people dislike tablets more than old

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell